A new design for a chronological release profile of etodolac from coated bilayer tablets: In-vitro and in-vivo assessment

Repeated dose medication usually maximizes adverse effects, while sustained release systems did not offer a fast onset of action. Etodolac was formulated to enable pulsatile and sustained drug release, which was chronologically more suitable as an anti-inflammatory drug. Eudragit® RSPO, Eudragit® RL...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgy, Kirolos R., Farid, Ragwa M., Latif, Randa, Bendas, Ehab R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300462/
https://www.ncbi.nlm.nih.gov/pubmed/30581611
http://dx.doi.org/10.1016/j.jare.2018.08.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300462/
https://www.ncbi.nlm.nih.gov/pubmed/30581611
http://dx.doi.org/10.1016/j.jare.2018.08.003

Ejemplares similares